))
S3 E1 - Sameek Roychowdhury, MD PhD – FGFR inhibitors: Mechanism and Activity on Resistance Mutations
Manage episode 407348222 series 3559566
Sisällön tarjoaa Karger Publishers. Karger Publishers tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
This is the first episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management.
In this episode, Dr. Sameek Roychowdhury discusses fibroblast growth factor receptor (FGFR) inhibitors in the management of cholangiocarcinoma—how long they’ve been in use, and what we know about their efficacy and toxicity. He uses his clinical experience to share what clinicians really need to know about this treatment, and what to do when disease progresses while on this treatment.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.
17 jaksoa
Jaa
